10488 related articles for article (PubMed ID: 11015990)
21. Analysis of T cell receptors reactive with squamous cell carcinoma antigen SART-1 presented by the HLA-A24 molecule.
Shimizu K; Yamaguchi Y; Ohta K; Miyahara E; Toge T
Oncol Rep; 2002; 9(3):599-605. PubMed ID: 11956635
[TBL] [Abstract][Full Text] [Related]
22. Response of established human breast tumors to vaccination with mammaglobin-A cDNA.
Narayanan K; Jaramillo A; Benshoff ND; Campbell LG; Fleming TP; Dietz JR; Mohanakumar T
J Natl Cancer Inst; 2004 Sep; 96(18):1388-96. PubMed ID: 15367572
[TBL] [Abstract][Full Text] [Related]
23. Immune responses to human tumors: development of tumor vaccines.
Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
[TBL] [Abstract][Full Text] [Related]
24. [Generation of HER2 specific, HLA-A24 restricted CTLs derived from gastric cancer patients].
Mimura K; Kono K; Sugai H; Miyagawa N; Omata H; Fujii H; Matsumoto Y
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1802-4. PubMed ID: 14619524
[TBL] [Abstract][Full Text] [Related]
25. Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient.
Nagata Y; Hanagiri T; Takenoyama M; Fukuyama T; Mizukami M; So T; Ichiki Y; Sugaya M; Sugio K; Yasumoto K
Clin Cancer Res; 2005 Jul; 11(14):5265-72. PubMed ID: 16033845
[TBL] [Abstract][Full Text] [Related]
26. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
28. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
30. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
31. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope.
Kazaks A; Balmaks R; Voronkova T; Ose V; Pumpens P
Biotechnol J; 2008 Nov; 3(11):1429-36. PubMed ID: 18956370
[TBL] [Abstract][Full Text] [Related]
32. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
[TBL] [Abstract][Full Text] [Related]
34. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.
Ueda Y; Shimizu K; Itoh T; Fuji N; Naito K; Shiozaki A; Yamamoto Y; Shimizu T; Iwamoto A; Tamai H; Yamagishi H
Jpn J Clin Oncol; 2007 Feb; 37(2):140-5. PubMed ID: 17255158
[TBL] [Abstract][Full Text] [Related]
35. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma.
Komohara Y; Harada M; Ishihara Y; Suekane S; Noguchi M; Yamada A; Matsuoka K; Itoh K
Oncol Rep; 2007 Dec; 18(6):1463-8. PubMed ID: 17982631
[TBL] [Abstract][Full Text] [Related]
36. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
37. Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2 / neu: possible immunotherapy for colorectal carcinomas.
Tanaka H; Tsunoda T; Nukaya I; Sette A; Matsuda K; Umano Y; Yamaue H; Takesako K; Tanimura H
Br J Cancer; 2001 Jan; 84(1):94-9. PubMed ID: 11139320
[TBL] [Abstract][Full Text] [Related]
38. Generation of a human leukocyte antigen-A24-restricted antitumor cell with the use of SART-1 peptide and dendritic cells in patients with malignant brain tumors.
Yoshida S; Tanaka R
J Lab Clin Med; 2004 Oct; 144(4):201-7. PubMed ID: 15514588
[TBL] [Abstract][Full Text] [Related]
39. Expression of the SART1 tumor rejection antigen in renal cell carcinoma.
Shintaku I; Kawagoe N; Yutani S; Hoshi S; Orikasa S; Yoshizumi O; Itoh K
Urol Res; 2000 Jun; 28(3):178-84. PubMed ID: 10929426
[TBL] [Abstract][Full Text] [Related]
40. Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine.
Narita M; Kanda T; Abe T; Uchiyama T; Iwafuchi M; Zheng Z; Liu A; Kaifu T; Kosugi S; Minagawa M; Itoh K; Takahashi M
Int J Oncol; 2015 Apr; 46(4):1699-709. PubMed ID: 25625346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
